

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Consolidated Financial Results for the First Quarter of Fiscal Year Ending December 31, 2026 (Under Japanese GAAP)

May 14, 2026

Company name: EM SYSTEMS CO., LTD
 Securities code 4820 URL <https://emsystems.co.jp>
 Representative: (Title) President&Representative (Name) Hiromasa Kunimitsu
 Director
 Inquiries (Title) Senior Executive Officer, Chief of Business Strategy Headquarters Kobayashi (Name) Daigo TEL +81(0)6-6397-1888
 Scheduled date to commence dividend payments: -
 Preparation of supplementary material on financial results: Yes
 Holding of financial results presentation: None

(Amounts of less than one million yen are rounded down.)

1. Consolidated results of December 31, 2026 1st quarter period (January 1st, 2026 through March 31st, 2026)

(1) Consolidated operating results (Cumulative)

(Percentage indicate YoY changes)

	Revenue		Operating profit		Ordinary profit		Attributable to owners of parent Quarterly net income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Three months ended March 31, 2026	5,039	(24.9)	216	(85.9)	388	(77.2)	155	(86.4)
March 31, 2025	6,714	20.5	1,533	112.8	1,701	94.8	1,139	99.3

(Note) Comprehensive income For the first quarter of the fiscal year ending December 2026: 267 million yen ((76.6%)) For the first quarter of the fiscal year ended December 2025: 1,140 million yen (98.8%)

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
March 31, 2026	2.24	2.23
March 31, 2025	16.48	16.42

(2) Consolidated financial positions

	Total assets	Equity	Equity to total assets ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
March 31, 2026	26,313	19,178	72.5	275.57
December 31, 2025	27,506	20,432	73.9	293.77

(Reference) Owner's equity For the first quarter of the fiscal year ending December 2026: 19,075 million yen For the fiscal year ended December 2025: 20,334 million yen

2. Cash dividends

	Annual dividends per share				
	End of first quarter	End of second quarter	End of third quarter	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended December 31, 2025	-	17.00	-	22.00	39.00
Fiscal year ending December 31, 2026	-				
Fiscal year ending December 31, 2026 (Forecast)		5.00	-	18.00	23.00

(Note) Presence or absence of revisions from the most recently announced dividend forecast: Yes

3. Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2026 (from January 01, 2026 to December 31, 2026)

(Percentages indicate YoY changes)

	Revenue		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Second quarter (cumulative)	10,273	(15.4)	447	(78.5)	791	(67.0)	344	(78.5)	4.97
Fiscal year ending December 31, 2026	22,762	(3.8)	3,316	(9.8)	3,939	(8.7)	2,193	(10.6)	31.69

(Note) Correction of financial forecast from the most recent financial forecast: Yes

* Notes

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: 1 company (Company name: Conduct Co., Ltd.), Excluded: None (Company name: -)

(2) Application of specific accounting for the consolidated quarterly financial statements: Yes

(Note) For details, please refer to the attached document on page 9, "2. Quarterly Consolidated Financial Statements and Main Notes (3) Notes on Quarterly Consolidated Financial Statements (Notes on Accounting Treatments Specific to the Preparation of Quarterly Consolidated Financial Statements)."

(3) Changes in accounting policies, changes in accounting estimates, retrospective restatement

(i) Changes in accounting policies due to revisions of accounting standards : None

(ii) Changes in accounting policies other than (i): None

(iii) Changes in accounting estimates : None

(iv) Retrospective restatement : None

(4) Number of shares issued (common stock)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of March 31, 2026	70,514,800 shares
As of December 31, 2025	70,514,800 shares

(ii) Number of treasury shares at the end of the period

As of March 31, 2026	1,293,795 shares
As of December 31, 2025	1,293,794 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Three months ended March 31, 2026	69,221,005 shares
Three months ended March 31, 2025	69,129,906 shares

※ Review of attached consolidated quarterly financial statements by a certified public accountant or an audit firm: None

* Notes regarding the appropriate use of forecasts and other special items

(Cautionary Statement Regarding Forward-Looking Statements)

The forward-looking statements, including earnings forecasts, contained in this document are based on information currently available to the Company and on certain assumptions deemed reasonable. They are not intended as a guarantee of achievement by the Company. Actual results may differ significantly due to various factors.

○Table of Contents of Attached Materials	
1. Overview of Operating Results, etc.	2
(1) Overview of operating results for the quarter	2
(2) Overview of financial positions for the quarter	3
(3) Explanation regarding forward-looking statements such as consolidated forecasts	3
2. Quarterly Consolidated Financial Statements and Main Notes	4
(1) Quarterly Consolidated Balance Sheet	4
(2) Quarterly Consolidated Statement of Income and Quarterly Consolidated Statement of Comprehensive Income	5
Quarterly Consolidated Statement of Income	6
Quarterly Consolidated Statement of Comprehensive Income	6
(3) Notes to the quarterly consolidated financial statements	7
(Notes regarding the assumption of a going concern)	7
(Notes in case of significant changes in the amount of shareholders' equity)	7
(Notes on quarterly consolidated statement of cash flows)	7
(Notes on segment information, etc.)	8
(Notes on accounting treatments specific to the preparation of quarterly consolidated financial statements)	9

1. Overview of Operating Results, etc.

(1) Overview of operating results for the quarter

In the medical industry, which is the main customer base of our group during the three months ended May 20, 2024, the social implementation of medical DX based on initiatives such as the "Medical DX Reiwa Vision 2030" is accelerating. Improving the stability and sustainability of the medical insurance system through efficiency and optimization has become an urgent issue, and the importance of system investment aimed at strengthening management foundations is increasing further.

Under such circumstances, our group has continued its efforts to promote medical DX and innovation, aiming to realize high-quality medical care. During the three months ended May 20, 2024, the implementation of the online eligibility verification system and electronic prescriptions, which had driven revenue in previous years, has reached a certain level of completion. However, we have continued to respond to various fee revisions and have promoted the development and provision of new value-added services utilizing advanced technologies such as generative AI.

In each segment of our group's businesses, we implemented organizational restructuring through the introduction of a company system to achieve the "Medium-Term Management Plan FY2025–FY2027," thereby accelerating decision-making in each segment and establishing a structure to provide optimal services that promptly respond to customer needs. In addition, we promoted the introduction of AI tools in call centers, conducted efficient system operation training utilizing online platforms, and promoted the use of AI in internal operations, aiming to enhance service quality and strengthen our profit structure through improved operational efficiency. For the three months ended May 20, 2024, initiatives such as the introduction of the online eligibility verification system and electronic prescriptions have run their course, resulting in a reactionary decline, and, due to a shift in sales strategies aimed at expanding our future revenue base, both net sales and operating profit fell below the levels of the same period of the previous year.

As a result, operating results for the three months ended May 20, 2024 were as follows: net sales of 5,039 million yen (down 24.9% YoY), operating profit of 216 million yen (down 85.9% YoY), ordinary profit of 388 million yen (down 77.2% YoY), and profit attributable to owners of parent of 155 million yen (down 86.4% YoY).

Operating results by segment are as follows.

(Pharmacy System Business)

With regard to the pharmacy system business, in addition to the fact that the concentrated demand associated with the installation of optional software related to the online eligibility verification system and electronic prescriptions has run its course, sales resources were strategically allocated to acquiring new customers from competitors and to value-added products, while efforts to promote replacement among existing customers were restrained. As a result, net sales and operating profit decreased.

As a result, for the three months ended May 20, 2024, the Dispensing Systems Business recorded net sales of 4,074 million yen (down 25.8% YoY) and operating profit of 374 million yen (down 74.4% YoY).

(Medical System Business)

Regarding the Medical Systems Business, the concentrated demand for electronic prescriptions, which was active in the previous fiscal year, has subsided. In addition, we prioritized shifting from promoting replacements among existing customers to acquiring new customers from other companies, resulting in a decrease in net sales and a loss in terms of profit. On the other hand, through the restructuring of our organizational system and the promotion of strategic approaches utilizing digital marketing, the number of paying customers for "MAPs for CLINIC" has been steadily increasing, and paid net sales are progressing smoothly.

As a result, for the three months ended May 20, 2024, the Medical Systems Business recorded net sales of 592 million yen (down 28.8% YoY), and an operating loss of 170 million yen (compared to operating profit of 123 million yen in the same period of the previous year).

(Nursing care/Welfare System Business)

Regarding the nursing care/welfare system business, as a result of promoting the replacement to "MAPs for NURSING CARE," although there was a decrease in sales of maintenance service during the transition period, net sales from subscription fees steadily increased due to the revision of the pricing structure accompanying the optimization of the revenue structure.

As a result, in the Nursing Care/Welfare System Business for the three months ended May 20, 2024, net sales were 133 million yen (up 4.2% YoY), and operating loss was 76 million yen (compared to an operating loss of 97 million yen in the same period of the previous year).

(Other businesses)

As for other businesses, although net sales decreased at Unike Software Research Co., Ltd. due to efforts to optimize management resources, profitability improved. In addition, as Choki Co., Ltd. maintained steady performance, the segment's net sales saw only a slight decrease, while operating profit increased.

As a result, for the three months ended May 20, 2024, net sales in other businesses were 279 million yen (down 6.2% YoY), and operating profit was 40 million yen (up 76.4% YoY).

(The Net sales and Operating profit (loss) by segment above are amounts before elimination of inter-segment transactions.)

(2) Overview of financial positions for the quarter

(Assets)

At the end of the first quarter of the consolidated fiscal period, current assets amounted to 11,439 million yen, a decrease of 1,508 million yen compared to the end of the previous consolidated fiscal year. This was mainly due to a decrease of 714 million yen in cash and deposits and a decrease of 691 million yen in other current assets. Non-current assets amounted to 14,874 million yen, an increase of 316 million yen compared to the end of the previous consolidated fiscal year. This was mainly due to an increase of 44 million yen in property, plant and equipment and an increase of 266 million yen in intangible assets.

As a result, total assets amounted to 26,313 million yen, a decrease of 1,192 million yen compared to the end of the previous fiscal year.

(Liabilities)

Current liabilities at the end of the first quarter of the consolidated fiscal period were 5,573 million yen, a decrease of 196 million yen compared to the end of the previous consolidated fiscal year. This was mainly due to a decrease in accounts payable by 349 million yen, although provision for bonuses increased by 192 million yen. Non-current liabilities were 1,562 million yen, an increase of 258 million yen compared to the end of the previous consolidated fiscal year. This was mainly due to an increase in long-term borrowings by 253 million yen.

As a result, total liabilities amounted to 7,135 million yen, an increase of 61 million yen compared to the end of the previous fiscal year.

(Net assets)

Net assets as of the end of the first quarter of the consolidated fiscal period were 19,178 million yen, a decrease of 1,254 million yen compared to the end of the previous consolidated fiscal year. This was mainly due to a decrease of 1,366 million yen in retained earnings.

As a result, the equity to total assets ratio was 72.5% (73.9% at the end of the previous fiscal year).

(3) Explanation regarding consolidated forecasts and other forward-looking information

Regarding the consolidated forecasts for the fiscal year ending December 2026, based on the results to date and the recent business environment, we have revised the forecasts for the six months ending June 30, 2026. For details, please refer to the "Notice Regarding Revision of Consolidated Forecasts and Dividend Forecasts for the Six Months Ending June 30, 2026" announced today (May 14, 2026).

There are no changes to the consolidated forecasts for the full fiscal year ending December 2026 from those announced in the "Financial Results for the Fiscal Year Ending December 2025" released on February 13, 2026.

2. Quarterly Consolidated Financial Statements and Main Notes (1) Quarterly Consolidated Balance Sheet

(Unit: Million yen)

	Previous fiscal year (December 31, 2025)	For the three months ended (March 31, 2026)
Assets		
Current assets		
Cash and deposit	7,847	7,133
Notes and trade receivables	3,207	3,065
Merchandise and finished goods	455	496
Others	1,441	750
Allowance for doubtful accounts	(4)	(6)
Total current asset	12,948	11,439
Non-current assets		
Property, plant, and equipment		
Buildings and structures, net	572	627
Land	348	367
Leased assets, net	2	2
Construction in progress	9	-
Other (net)	442	423
Total property, plant and equipment, net	1,376	1,420
Intangible assets		
Software	749	880
Software in progress	160	21
Goodwill	2,063	2,340
Other	1,047	1,045
Total intangible assets	4,021	4,287
Investment Other assets		
Investment securities	1,043	1,149
Investment property, net	6,469	6,444
Others	1,660	1,586
Allowance for doubtful accounts	(12)	(12)
Total investment and other assets	9,160	9,167
Total non-current assets	14,558	14,874
Total assets	27,506	26,313

(Unit: Million yen)

	Previous fiscal year (December 31, 2025)	For the three months ended (March 31, 2026)
Liabilities		
Current liabilities		
Notes and accounts payable - trade	1,181	1,235
Current portion of long-term borrowings	577	466
Accounts payable	1,361	1,011
Lease liabilities	0	0
Income taxes payable	128	163
Provision for bonuses	465	657
Contract liabilities	816	799
Others	1,237	1,237
Total current liabilities	5,769	5,573
Non-current liabilities		
Long-term borrowings	5	258
Lease liabilities	2	2
Liabilities for retirement benefits	132	138
Provision for product warranties	0	0
Long-term guarantee deposits	814	815
Other	348	346
Total non-current liabilities	1,304	1,562
Total liabilities	7,074	7,135
Net assets		
Shareholders' equity		
Share capital	2,785	2,785
Capital surplus	2,502	2,502
Retained earnings	15,290	13,924
Treasury shares	(711)	(711)
Total shareholders' equity	19,867	18,501
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	282	362
Foreign currency translation adjustment	184	211
Total accumulated other comprehensive income	467	574
Share acquisition rights	55	55
Non-controlling interests	41	47
Total net assets	20,432	19,178
Total liabilities and net assets	27,506	26,313

(2) Quarterly Consolidated Statement of Income and Quarterly Consolidated Statement of Comprehensive Income
(Quarterly Consolidated Statement of Income)

(Unit: Million yen)

	For the three months ended [previous period] From January 1, 2025 Until March 31, 2025	For the three months ended From January 1, 2026 Until March 31, 2026
Revenue	6,714	5,039
Cost of sales	2,952	2,744
Gross profit	3,761	2,294
Selling, general and administrative expenses	2,228	2,078
Operating profit	1,533	216
Non-operating income		
Interest income	1	9
Real estate lease revenue	268	276
Other	3	4
Total non-operating income	272	291
Non-operating expenses		
Interest expense	2	0
Real estate lease expenses	101	115
Others	0	2
Total non-operating expenses	104	118
Ordinary profit	1,701	388
Extraordinary income		
Gain on sale of non-current assets	0	-
Total extraordinary income	0	-
Extraordinary losses		
Loss on retirement of fixed assets	0	4
Impairment losses	44	97
Total extraordinary losses	45	102
Net income before income taxes	1,656	286
Income taxes	512	126
Net income	1,143	160
Net income attributable to non-controlling interests	4	5
Profit attributable to owners of parent	1,139	155

(Quarterly Consolidated Statement of Comprehensive Income)

(Unit: Million yen)

	For the three months ended [previous period end date] From January 1, 2025 until March 31, 2025	For the three months ended From January 1, 2026 Until March 31, 2026
Net income	1,143	160
Other comprehensive income (loss), net of tax		
Valuation difference on available-for-sale securities	41	79
Foreign currency translation adjustment	(44)	26
Other comprehensive income, net of tax	(3)	106
Comprehensive income	1,140	267
Profit attributable to		
Quarterly comprehensive income attributable to owners of the parent	1,135	261
Quarterly comprehensive income attributable to non-controlling interests	4	5

(3) Notes to the quarterly consolidated financial statements

(Notes regarding the assumption of a going concern)

There are no applicable matters.

(Notes in case of significant changes in the amount of shareholders' equity)

There are no applicable matters.

(Notes on quarterly consolidated statement of cash flows)

The quarterly consolidated statement of cash flows for the three months ended has not been prepared. Depreciation (including amortization of intangible assets other than goodwill) and amortization of goodwill for the three months ended are as follows.

	For the three months ended [previous fiscal quarter end date] From January 1, 2025 Until March 31, 2025	For the three months ended From January 1, 2026 until March 31, 2026
Depreciation	266 million yen	205 million yen
Amortization of goodwill	48 million yen	65 million yen

(Notes on segment information, etc.)

[Segment Information]

I For the three months ended March 31, 2025

1. Information on net sales and profit or loss by reportable segment, and breakdown of revenue

(Unit: Million yen)

	Reportable segment					Adjustment amount (Note) 1	Quarterly Consolidated Statement of income Recorded amount
	Pharmacy Systems Business	Medical System Business	Nursing care/Welfare Systems Business	Other businesses	Total		
Revenue							
Initial sales	3,024	576	20	-	3,621	-	3,621
Subscription sales	1,775	223	55	-	2,054	-	2,054
Supply sales	526	14	-	-	541	-	541
Maintenance sales	159	17	51	-	229	-	229
Other business revenue	-	-	-	268	268	-	268
From contracts with customers Revenue generated	5,486	831	127	268	6,714	-	6,714
Net sales to external customers	5,486	831	127	268	6,714	-	6,714
Internal net sales or transfers between segments	4	-	-	30	34	(34)	-
Total	5,490	831	127	298	6,748	(34)	6,714
Segment profit or loss (-) (Note) 2	1,459	123	(97)	22	1,508	24	1,533

(Note) 1. The adjustment amount for segment profit or loss is due to elimination of inter-segment transactions, etc.

2. Segment profit or loss is adjusted with operating profit in the quarterly consolidated statement of income.

2. Information on impairment losses of non-current assets or goodwill, etc. by reportable segment

(Significant impairment losses related to non-current assets)

(Unit: Million yen)

	Pharmacy Systems Business	Medical System Business	Nursing care/Welfare Systems Business	Other businesses	Total
Impairment losses	-	9	35	-	44

(Significant changes in the amount of goodwill)

There are no applicable matters.

(Significant gain on bargain purchase)

There are no applicable matters.

II For the three months ended March 31, 2026

1. Information on net sales and profit or loss by reportable segment, and breakdown of revenue

(Unit: Million yen)

	Reportable segment					Adjustment amount (Note) 1	Quarterly Consolidated Statement of income Recorded amount
	Pharmacy Systems Business	Medical System Business	Nursing care/Welfare System Business	Other businesses	Total		
Revenue							
Initial sales	1,668	308	15	-	1,992	-	1,992
Subscription sales	1,801	256	83	-	2,142	-	2,142
Supply sales	474	12	-	-	486	-	486
Maintenance sales	124	14	34	-	172	-	172
Other business revenue	-	-	-	244	244	-	244
From contracts with customers Revenue generated	4,068	592	133	244	5,039	-	5,039
Net sales to external customers	4,068	592	133	244	5,039	-	5,039
Internal net sales or transfers between segments	5	-	-	35	40	(40)	-
Total	4,074	592	133	279	5,080	(40)	5,039
Segment profit or loss (-) (Note) 2	374	(170)	(76)	40	167	49	216

(Note) 1. The adjustment amount for segment profit or loss is due to elimination of inter-segment transactions, etc.

2. Segment profit or loss is adjusted with operating profit in the quarterly consolidated statement of income.

2. Information on impairment losses of non-current assets or goodwill, etc. by reportable segment

(Significant impairment losses related to non-current assets)

(Unit: Million yen)

	Pharmacy Systems Business	Medical System Business	Nursing care/Welfare Systems Business	Other businesses	Total
Impairment losses	-	90	6	-	97

(Significant changes in the amount of goodwill)

In the "Nursing Care/Welfare System Business" segment, goodwill of 341 million yen was recorded in the first quarter of the consolidated cumulative period as a result of acquiring shares of Conduct Co., Ltd. and making it a consolidated subsidiary.

Note: As of the end of the first quarter of the consolidated fiscal period, the amount of goodwill is a provisional figure, as the allocation of the acquisition cost has not been completed.

(Significant gain on bargain purchase)

There are no applicable matters.

(Notes on accounting treatments specific to the preparation of quarterly consolidated financial statements)

(Calculation of tax expenses)

With regard to income tax expenses, the effective tax rate after applying tax effect accounting for the consolidated fiscal year including the first quarter consolidated accounting period is reasonably estimated, and the estimated effective tax rate is applied to the pre-tax net income to calculate the tax expenses.